Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea

Area of Science:

• Respiratory Medicine
• Sleep Medicine
• Pharmacology

Background:

• Obstructive sleep apnea (OSA) is a common disorder linked to airway collapse during sleep.
• The precise mechanisms by which acetazolamide may improve OSA are not fully understood.
• Investigating acetazolamide's effects on OSA's underlying physiological traits is crucial for targeted treatment.

Purpose of the Study:

• To determine how acetazolamide influences the physiological traits contributing to obstructive sleep apnea (OSA).
• To assess the impact of acetazolamide on OSA severity, measured by the apnea-hypopnea index (AHI).

Main Methods:

• A cohort of 13 OSA patients received acetazolamide (500 mg twice daily) for one week.
• Key traits evaluated included pharyngeal collapsibility, loop gain (LG), upper-airway responsiveness, and arousal threshold using CPAP pressure drops.
• Apnea-hypopnea index (AHI) was measured via polysomnography.

Main Results:

• Acetazolamide significantly reduced median loop gain (LG) and NREM AHI.
• No significant changes were observed in pharyngeal anatomy/collapsibility, upper-airway gain, or arousal threshold.
• A moderate correlation was found between reduced LG and reduced AHI.

Conclusions:

• Acetazolamide demonstrates potential in improving obstructive sleep apnea (OSA).
• The therapeutic effect is likely mediated by a reduction in the sensitivity of the ventilatory control system (lowering loop gain).
• Future strategies may involve identifying patients who benefit from LG reduction for pharmacological OSA management.